Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,237 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Disorder Clear all
Not listed No phase listed Observational

Seizure Detection and Warning System for Epilepsy Patients

NCT01874600
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Sentinel Seizure Detection Device and Warning System
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
13 Years to 21 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

NCT01969851
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 22, 2026, 5:15 AM EDT
Completed No phase listed Interventional Results available

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System

NCT05034731
View directory record Official record
Conditions
Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
Interventions
Remote Fitting, In-Office Fitting
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
13 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

NCT00520741
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
108
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Neurology Inpatient Clinical Education Trial

NCT03826056
View directory record Official record
Conditions
Myasthenia Gravis, Guillain-Barre Syndrome, Multiple Sclerosis, Seizures, Parkinsonism, Meningitis, Encephalitis, Headache, Vestibular Disorder, Spondylosis, Normal Pressure Hydrocephalus
Interventions
Current standard discharge educational intervention, Personalized discharge educational intervention
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Antiepileptic Drugs and Osteoporotic Prevention Trial

NCT00869622
View directory record Official record
Conditions
Epilepsy, Bone Loss, Osteoporosis, Fractures
Interventions
Risedronate, Placebo + Calcium and Vitamin D
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

NCT01339559
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Project UPLIFT for Psychogenic Non-Epileptic Seizures

NCT03329703
View directory record Official record
Conditions
Psychogenic Non-Epileptic Seizure, Depression, Non-Epileptic Seizure, Psychogenic Seizure
Interventions
Project UPLIFT
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 22, 2026, 5:15 AM EDT
Withdrawn Phase 2 Interventional

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

NCT01997255
View directory record Official record
Conditions
Sturge Weber Syndrome
Interventions
Everolimus
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

NCT01261325
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 22, 2026, 5:15 AM EDT
Completed No phase listed Observational

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

NCT00001489
View directory record Official record
Conditions
Epilepsy, Epilepsy, Complex Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

NCT07847918
View directory record Official record
Conditions
SLC6A1
Interventions
Glycerol Phenylbutyrate
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
2 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

COPE Intervention for Parents of Children With Epilepsy

NCT00767026
View directory record Official record
Conditions
Epilepsy
Interventions
COPE (Creating Opportunities for Parent Empowerment), Standard education
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 22, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

NCT07019922
View directory record Official record
Conditions
Epileptic Encephalopathy, SCN2A Encephalopathy
Interventions
1mg elsunersen, 0.5mg elsunersen
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 5:15 AM EDT
Recruiting Early Phase 1 Interventional

Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy

NCT05493722
View directory record Official record
Conditions
Refractory Epilepsy, Deep Brain Stimulation
Interventions
Physician-Selected Settings Stimulation, Optimized Settings Stimulation, DBS Setting Optimization
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, levetiracetam, lorazepam, placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Apioc Contact Lens Feasibility

NCT03688672
View directory record Official record
Conditions
Ametropia, Myopia, Hyperopia, Astigmatism, Presbyopia
Interventions
Apioc Contact Lens Design
Device
Lead sponsor
Lentechs, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 22, 2026, 5:15 AM EDT
Not listed Phase 4 Interventional

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

NCT04118829
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Perampanel
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Low Frequency TMS for Depression in Epilepsy

NCT03105700
View directory record Official record
Conditions
Epilepsy, Depressions, Refractory
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

NCT00535392
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Chesterfield, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Oct 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Spatiotemporal Dynamics of the Human Emotion Network

NCT05152992
View directory record Official record
Conditions
Epilepsy, Depression, Anxiety, Emotions
Interventions
Viewing visual stimuli and electrical stimulation of the brain
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 5:15 AM EDT